1) as always continuation of some sort of billing pass through for Omidria ... what would a considered investor be looking for here, some sort of payment schedule event?
2) continued rolling BLA submission of narsoplimab for HSCT-TMA, remind me is this just basically down to CMC now?
3) some notions of COVID applications, I'm just not (and unlikely to) following that, am I a fool for not considering this?
4) the other indications, and the MASP3 pipeline off in the distance, is this 2025 and beyond?
I know I just need to revist and put on some glasses read some and catch up, but I figured I would stir the pot here first.